Number of the records: 1
Immunotherapy of MHC class I-deficient tumors
- 1.
SYSNO ASEP 0352661 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Immunotherapy of MHC class I-deficient tumors Author(s) Reiniš, Milan (UMG-J) RID Source Title Future Oncology - ISSN 1479-6694
Roč. 6, č. 10 (2010), s. 1577-1589Number of pages 13 s. Language eng - English Country GB - United Kingdom Keywords tumor vaccine ; MHC class I expression ; antigen presenting machinery Subject RIV EB - Genetics ; Molecular Biology R&D Projects GA301/07/1410 GA ČR - Czech Science Foundation (CSF) GAP301/10/2174 GA ČR - Czech Science Foundation (CSF) IAA500520807 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR) IAA500520605 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR) CEZ AV0Z50520514 - UMG-J (2005-2011) UT WOS 000284192800011 DOI 10.2217/FON.10.128 Annotation MHC class I downregulation is a general mechanism by which tumor cells can escape from T-cell-mediated immunity. Therefore, successful imunotherapeutic and vaccination protocols should be optimized against tumors with distinct cell surface expression of the MHC class I molecules. Mechanisms leading to protective immunity may vary in different models with respect to the particular tumors, e.g. to their levels of residual expression of the MHC class I molecules on tumor cells or inducibility of MHC class I expression. Notably, both CD8+ cell-mediated immunity and MHC class I-unrestricted mechanisms can take place against MHC class I-deficient tumors. Since MHC class I downregulation is frequently reversible by cytokines and also by activation of epigenetically silenced genes, an attractive strategy is to elicit specific cell-mediated immunity combined with restoration of MHC class I expression on tumor cells. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2011
Number of the records: 1